Understanding BTK Inhibitor Resistance in CLL
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Released: October 01, 2024

Expiration: September 30, 2025

Matthew S Davids
Matthew S Davids, MD, MMSc
Lindsey Roeker
Lindsey Roeker, MD

Activity

Progress
1
Course Completed

In this episode, listen to Matthew S. Davids, MD, MMSc​, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:

  • Contemporary treatment paradigms for patients with CLL
  • Safety and efficacy of current regimens
  • Molecular testing, including when and how to test for BTK inhibitor resistance
  • Considering BTK inhibitor resistance when sequencing therapy